Page 1

PRESS RELEASE ● ● affi med ● Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress AFM13 monotherapy : Enrollment is on track and expected to be completed in the first half of 2022 . AFM13 combination with NK cells : Protocol amendment submitted to expand the trial to treat up to 40 patients with Hodgkin and non - Hodgkin Lymphoma at the highest dose . Updated data to be presented at company - sponsored event in mid December 2021 . AFM24 monotherapy : Identified recommended Phase 2 dose ( 480 mg weekly ) ; expansion cohorts to open during the fourth quarter of 2021 . AFM24 combination with anti PD - L1 checkpoint inhibitor : Clinical trial of AFM24 with atezolizumab ( Tecentriq® ) on track to start in fourth quarter of 2021 . AFM24 combination with NK cells : Initiated recruitment for the clinical trial of AFM24 in combination with NKGen Biotech's SNK01 NK cell therapy . AFM28 : AFM28 targets CD123 , which is universally expressed on blasts and leukemic stem cells ( LSCs ) in AML . Initial preclinical data to be presented at American Society of Hematology conference in December 2021 . Cash and cash equivalents as of September 30 , 2021 , were approximately € 198.7 million with anticipated cash runway into the second half of 2023 . ● Conference call and webcast scheduled for November 10 , 2021 , at 8:30 a.m. EST . Heidelberg , Germany , November 10 , 2021 - Affimed N.V. ( Nasdaq : AFMD ) , a clinical - stage immuno - oncology company committed to giving patients back their innate ability to fight cancer , today reported financial results for the quarter ended September 30 , 2021 , and provided an update on clinical and corporate progress . " In the past months , we have significantly expanded our efforts to ensure the development of our leading candidates , AFM13 and AFM24 , which we believe will result in multiple catalysts over the next several quarters , " said Adi Hoess , CEO of Affimed . " We are excited about AFM28 , a ROCK® platform - based ICE® , which we believe will be a novel and promising approach for difficult - to - treat AML patients . We know NK cells have shown some activity in AML and , coupled with what we are seeing in the AFM13 study in combination with NK cells we are